Cerevel Therapeutics Holdings CEO N Coles' 2021 pay jumps 990% to $8.1M
Cerevel Therapeutics Holdings reports 2021 executive compensation
By ExecPay News
Published: April 28, 2022
Cerevel Therapeutics Holdings reported fiscal year 2021 executive compensation information on April 28, 2022.
In 2021, six executives at Cerevel Therapeutics Holdings received on average a compensation package of $4.1M, a 53% increase compared to previous year.
Average pay of disclosed executives at Cerevel Therapeutics Holdings
N. Anthony Coles, Chief Executive Officer, received $8.1M in total, which increased by 196% compared to 2020. 88% of Coles' compensation, or $7.1M, was in option awards. Coles also received $391K in non-equity incentive plan and $618K in salary.
Abraham Ceesay, President, received a compensation package of $5.3M. 85% of the compensation package, or $4.5M, was in option awards.
Kathy Yi, Chief Financial Officer, earned $3.5M in 2021.
Raymond Sanchez, Chief Medical Officer, received $3.4M in 2021, which increases by 93% compared to 2020.
Scott Akamine, Chief Legal Officer, earned $3.2M in 2021.
Mark Bodenrader, Chief Financial Officer, received $1.3M in 2021.
Related executives
N Coles
Cerevel Therapeutics Holdings
Chief Executive Officer
Mark Bodenrader
Cerevel Therapeutics Holdings
Chief Financial Officer
Kathy Yi
Cerevel Therapeutics Holdings
Chief Financial Officer
Abraham Ceesay
Cerevel Therapeutics Holdings
President
Raymond Sanchez
Cerevel Therapeutics Holdings
Chief Medical Officer
Scott Akamine
Cerevel Therapeutics Holdings
Chief Legal Officer
You may also like
Source: SEC filing on April 28, 2022.